Literature DB >> 19738008

Reconsidering some approved antimicrobial agents for tuberculosis.

Lowell S Young1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19738008      PMCID： PMC2772312          DOI： 10.1128/AAC.00887-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  15 in total

Review 1.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

2.  Tuberculosis and trimethoprim-sulfamethoxazole.

Authors:  Pierre Forgacs; Nancy L Wengenack; Leslie Hall; Sarah K Zimmerman; Mark L Silverman; Glenn D Roberts
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Activity of amoxicillin/clavulanate in patients with tuberculosis.

Authors:  H F Chambers; T Kocagöz; T Sipit; J Turner; P C Hopewell
Journal:  Clin Infect Dis       Date:  1998-04       Impact factor: 9.079

5.  Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.

Authors:  L E Bermudez; P Kolonoski; M Wu; P A Aralar; C B Inderlied; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria.

Authors:  Lia Danelishvili; Martin Wu; Lowell S Young; Luiz E Bermudez
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

7.  Imipenem for treatment of tuberculosis in mice and humans.

Authors:  Henry F Chambers; Joan Turner; Gisela F Schecter; Masae Kawamura; Philip C Hopewell
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

9.  Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.

Authors:  Esteban C Nannini; Michael Keating; Peter Binstock; George Samonis; Dimitrios P Kontoyiannis
Journal:  J Infect       Date:  2002-04       Impact factor: 6.072

10.  New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.

Authors:  Andre Rosowsky; Ronald A Forsch; Carol Hopkins Sibley; Clark B Inderlied; Sherry F Queener
Journal:  J Med Chem       Date:  2004-03-11       Impact factor: 7.446
View more
  6 in total

1.  Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.

Authors:  Claudio U Köser; Richard N Veerapen-Pierce; David K Summers; John A C Archer
Journal:  Antimicrob Agents Chemother       Date:  2010-10       Impact factor: 5.191

Review 2.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

3.  Bacterial conversion of folinic acid is required for antifolate resistance.

Authors:  Sam Ogwang; Hoa T Nguyen; Marissa Sherman; Saralee Bajaksouzian; Michael R Jacobs; W Henry Boom; Guo-Fang Zhang; Liem Nguyen
Journal:  J Biol Chem       Date:  2011-03-03       Impact factor: 5.157

4.  The Pup-Proteasome System Protects Mycobacteria from Antimicrobial Antifolates.

Authors:  Marissa B Guzzo; Qing Li; Hoang V Nguyen; W Henry Boom; Liem Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

5.  Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis.

Authors:  Claudio U Köser; David K Summers; John A C Archer
Journal:  Antimicrob Agents Chemother       Date:  2010-11       Impact factor: 5.191

Review 6.  Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.

Authors:  Kerstin A Wolff; Liem Nguyen
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.